Novel Glaucoma Diagnostics (NCT00286637)
Novel Diagnostics for Ocular Structure
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Who can join: Review the eligibility criteria below.
Location: Wills Eye Hospital β Philadelphia, Pennsylvania
Age range: 18 Years
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Wills Eye Hospital β Philadelphia, Pennsylvania
π Contact the Study Coordinator
Phone: (215) 928-3197
Email: tharwood@willseye.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glaucoma
- Novel Markers for Detecting Early Progression of Glaucoma β Halifax, Nova Scotia
- Electrical Stimulation for the Treatment of Glaucoma β Palo Alto, California
- Visual Field Analysis With Artificial Intelligence β Alexandria, Virginia
- Anterior Segment Optical Coherence Tomography Microstent Positioning β Murray, Utah
- Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination β Santa Rosa de CopΓ‘n,
- Evaluate the Safety and Effectiveness of iSTAR Medical's MINIjectβ’ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. β Glendale, Arizona
Explore by condition: All Glaucoma clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.